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Objective: Pulmonary hypertension is commonly found in patients undergoing
valvular surgery and can be worsened by cardiopulmonary bypass. Inhaled epopro-
stenol (prostacyclin) has been used for the treatment of pulmonary hypertension, but
its effects compared with those of placebo on hemodynamics, oxygenation, echo-
cardiographic examination, and platelet function have not been studied during
cardiac surgery.
Methods: Twenty patients with pulmonary hypertension undergoing cardiac surgery
were randomized in a double-blind study to receive inhaled epoprostenol (60 g) or
placebo. The inhalation occurred after induction of anesthesia and before surgical
incision. The effects on left and right systolic and diastolic cardiac functions
evaluated by means of pulmonary artery catheterization and transesophageal echo-
cardiography, as well as oxygenation and platelet aggregation, were studied.
Results: Inhalation of epoprostenol significantly reduced indexed right ventricular
stroke work from 10.7  4.57 g  m  m2 to 7.8  3.94 g  m  m2 (P  .003) and
systolic pulmonary artery pressure from 48.4  18 mm Hg to 38.9  11.9 mm Hg
(P  .002). The effect was correlated with the severity of pulmonary hypertension
(r  0.76, P  .01) and was no longer apparent after 25 minutes. There was no
significant effect on systemic arterial pressures, left ventricular function, arterial
oxygenation, platelet aggregation, and surgical blood loss.
Conclusion: Inhaled epoprostenol reduces pulmonary pressure and improves right
ventricular stroke work in patients with pulmonary hypertension undergoing cardiac
surgery. A dose of 60 g is hemodynamically safe, and its effect is completely
reversed after 25 minutes. We did not observe any evidence of platelet dysfunction
or an increase in surgical bleeding after administration of inhaled epoprostenol.
Pulmonary hypertension (PH) is associated with an increase in mor-bidity and mortality in patients undergoing cardiac surgery.1 Manydrugs have been used in recent years to treat PH. Among these arevasodilators, including epoprostenol (prostacyclin; PGI2). However,its intravenous administration is limited by systemic hypotensionbecause of nonselective vasodilation and by hypoxemia through wors-
ening of intrapulmonary shunt caused by inhibition of hypoxic pulmonary vaso-
constriction.2,3
Inhaled PGI2 appears to be a selective pulmonary vasodilator comparable with
inhaled nitric oxide (iNO) but acting through cyclic adenosine monophosphate
instead of cyclic guanosine monophosphate.4,5 Its administration can be a simpler
and less expensive alternative to iNO. Its half-life is 2 to 3 minutes, and at
physiologic pH, it spontaneously hydrolyses to 6-ketoprostaglandin F1 (6-keto-
PGF1). Thus its effect remains localized to ventilated lung units, it can decrease
pulmonary artery pressure (PAP) without causing systemic hypotension and im-
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prove oxygenation by decreasing ventilation-perfusion mis-
match.5-8 Its effect on cardiac function when given by
means of inhalation is controversial but it can increase
cardiac output when given intravenously.9,10
Finally, a drawback of PGI2 is that it has been reported
to alter platelet function,11 which could be hazardous during
cardiac surgery.
We have previously reported our retrospective experi-
ence with the use of inhaled PGI2.12 However, so far no
study has evaluated its effects in patients undergoing car-
diac surgery and simultaneously on several important clin-
ical variables, such as the magnitude of its hemodynamic
effect and its consequences on echocardiographic indices of
right ventricular (RV) and left ventricular (LV) systolic and
diastolic functions, oxygenation, platelet function, and
bleeding.
Methods
Population
After approval by the research and ethics committee and obtaining
informed consent, 20 patients with PH undergoing cardiac surgery
with cardiopulmonary bypass were included in the study. Patients
were considered to have PH if systolic pulmonary artery pressure
(sPAP) was greater than 30 mm Hg or mean pulmonary artery
pressure was greater than 25 mm Hg, as measured during the
preoperative period or estimated by using Doppler echocardiogra-
phy.13 This was confirmed after insertion of a pulmonary artery
catheter and before induction of general anesthesia. Patients with
LV dysfunction (ejection fraction of 30%) or known bleeding
diathesis were excluded. Further exclusion criteria were contrain-
dications to transesophageal echocardiography (TEE), including
esophageal disease or unstable cervical spine. A Parsonnet score
was calculated for every patient.1
Protocol
Patients were premedicated with 1 to 2 mg of lorazepam admin-
istered orally 1 hour before the operation, as well as 0.1 mg/kg
morphine administered intramuscularly and 0.2 to 0.4 mg of sco-
polamine administered intramuscularly before being taken to the
operating room. In the operating room additional midazolam was
added (0.01-0.05 mg/kg administered intravenously) as needed for
patient comfort. Usual monitoring was installed, including a 5-lead
electrocardiogram, pulse oximeter, peripheral venous line, radial
arterial line, 15-cm 3-lumen catheter (CS-12703, Arrow Interna-
tional Inc, Reading, Calif), and fast-response thermodilution pul-
monary artery catheter (Swan-Ganz catheter 7.5F; Baxter Health-
care Corporation, Irvine, Calif). Anesthesia was induced with 0.04
mg/kg midazolam and 1 g/kg sufentanil, and muscle relaxation
was achieved with 0.1 mg/kg pancuronium. After tracheal intuba-
tion, anesthesia was maintained with 1 g  kg1  h1 sufen-
tanil and 0.04 mg  kg1  h1 midazolam. No anesthetic gases
were used. Minute ventilation was adjusted to maintain end-tidal
carbon dioxide between 30 and 40 mm Hg with an infrared carbon
dioxide analyzer. A 5.0-MHz TEE omniplane probe (Hewlett-
Packard Sonos 5500, Andover, Mass) was inserted after induction
of general anesthesia.
Drug Administration Protocol
Patients were equally divided into 2 groups to receive either
inhaled PGI2 or placebo in a double-blind randomized manner by
using a computer-generated randomization table. Epoprostenol
(Flolan; Glaxo-Wellcome Inc, Mississauga, Ontario, Canada) was
given as epoprostenol 1.5 mg of salt dissolved in sterile glycine
buffer diluent, for a concentration of 15 g/mL. Each patient
received 4 mL of a solution containing either PGI2 or normal
saline solution (placebo).
The study drug was administered through a jet nebulizer (Ref
8901; Salter Labs, Arvin, Calif) attached to the inspiratory limb of
the ventilator near the endotracheal tube. Nebulization was
achieved with a bypass flow of oxygen at 8 L/min. This high flow
was used to achieve a high proportion of small particles (5 m).
Because this added a secondary flow to the patient, minute venti-
lation was adjusted to maintain peak inspiratory pressures of less
than 30 cm H2O and a normal end-tidal carbon dioxide.
Measurements
Hemodynamic parameters included central venous pressure, PAP,
and pulmonary artery occlusion pressure. Cardiac output was
assessed by using the thermodilution technique with 3 injections of
room temperature dextrose 5% (10 mL) at end expiration. Sys-
temic vascular resistances, pulmonary vascular resistances, RV
stroke work, and LV stroke work were calculated by using a
standard formula. Hemodynamic values were indexed for patient
body surface area.
Arterial and mixed venous blood gases were obtained to mea-
sure pH, PO2, PCO2, HCO3, and SO2.
TEE examination was performed to evaluate systolic and dia-
stolic parameters of LV and RV performance. The TEE examina-
tion included a midesophageal 4-chamber view, a short-axis trans-
gastric view at the midpapillary level, and color flow Doppler
imaging of the mitral valve to detect any unsuspected significant
mitral valvulopathy. We first obtained a baseline transgastric short-
axis view of the left ventricle at the midpapillary level, followed by
a pulsed Doppler examination of pulmonary venous flow, trans-
mitral flow, transtricuspid flow, and hepatic venous flow. The
Doppler sample volume (2-mm width) was positioned in the left
upper pulmonary vein approximately 1 cm proximal to its entrance
into the left atrium to measure pulmonary venous flow by using
color Doppler flow to sample maximal flow. When necessary, to
minimize the angle between the Doppler beam and the pulmonary
vein’s long axis, we rotated the omniplane probe as far as needed
from the horizontal plane. This axis was maintained throughout the
examination. The same approach was used for hepatic venous
flow. Mitral and tricuspid inflow velocities were measured at the
tip of the atrioventricular valve leaflets. Three signals were ob-
tained, and the maximal value was computed for analysis.14 Two
independent observers were involved: the first one recorded he-
modynamic parameters, and the other, blinded to the hemody-
namic data and to the study drug, simultaneously recorded the
pulsed Doppler and 2-dimensional echocardiographic images. All
TEE examinations were performed by anesthesiologists who were
not in charge of the patient. After data recording, a third anesthe-
siologist blinded to all data reviewed the recorded sequence. All
2-dimensional images in which the LV and RV endocardial border
could not be traced adequately by using Schnittger criteria, in
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which 80% of the endocardial contour has to be visualized, were
excluded.15 In addition, the Doppler signals were reviewed and
rejected if they were not laminar and when a clear contour could
not be determined for quantification of the velocity-time integral.
Severe mitral stenosis or regurgitation were exclusion criteria for
the measurement of mitral inflow. All the anesthesiologists per-
forming the TEE measurements were board certified in perioper-
ative TEE. If disagreement occurred between 2 reviewers, a third
echocardiographer was asked to review the echocardiographic
sequence. Our experience and interobserver variability in the mea-
surement of systolic and diastolic function has been published
previously.16,17
Platelet aggregation studies were performed on whole blood by
using a Chronolog 560 whole blood lumi-aggregometer (Chro-
nolog Corp, Havertown, Pa). Sodium citrate, 0.5 mL of a 3.2%
solution, was added to 4.5 mL of venous blood. The citrated blood
was diluted 1:1 with normal saline solution. After the solution had
been cooled to 20°C to 25°C, a 900-L sample was placed in a
cuvette containing a silicone stir bar. After 3 minutes, 100 L of
chrono-lume (luciferase luciferon reagent, Chronolog Corp) was
added. After another 2 minutes, 2 mmol/L of adenosine triphos-
phate (ATP) was added. The ATP standard was then measured for
each patient. Two minutes later, an aggregant was added (20
mol/L adenosine diphosphate, 5 g/mL collagen, or 1 nmol/L
arachidonic acid), and platelet aggregation and ATP release (lu-
minescence) were measured. Blood loss was measured for the
intraoperative period, as well as for the first 24 hours postopera-
tively.
Hemodynamic parameters were measured before (T1) and 10
minutes after (T2) induction of anesthesia, after nebulization of
PGI2 or placebo (T3), and 15 (T4) and 25 (T5) minutes after
nebulization. Arterial and mixed venous blood gases were obtained
at the same times, except for T5. TEE examination and platelet
aggregation studies were performed before and after administra-
tion of PGI2 or placebo. Patients were observed until discharge
from the intensive care unit.
Statistical Analysis
Population size was calculated for a power of 80% and an  error
of .05, assuming an sPAP of 40  4 mm Hg to decrease by 20%
in the PGI2 group and remain stable in the placebo group.
Continuous variables were analyzed with the Student t test and
categoric variables with the 2 or Fisher exact test. Two-factor
(time and group) repeated-measures analysis of variance was used
to determine time variations between the 2 groups. In case of
significant interaction, time  group comparison was performed
with Bonferroni corrections.
The Pearson correlation test was performed to determine the
relationship between the level of sPAP and the degree of reduction
of sPAP after PGI2 and placebo administration.
Results
Twenty-seven patients were enrolled in the study. Four were
later not randomized because they failed to meet the inclu-
sion criteria for PH on arrival to the operating room. Two
were excluded because the operation was subsequently re-
scheduled and another because of agitation. Demographic
variables were similar in both groups (Table 1).
Hemodynamics
Baseline hemodynamic variables were similar between the
2 groups (Table 2). Baseline sPAP was 61.2  19 mm Hg
in the PGI2 group and 54.3  14.6 mm Hg in the placebo
group (P  .4). These decreased significantly after induc-
tion of anesthesia in both groups to 48.4  18 mm Hg and
42.7  12.8 mm Hg, respectively. After administration of
the study drug, a decrease was noted in the PGI2 group to
38.9  11.9 mm Hg (P  .002), as opposed to that seen in
the placebo group. Fifteen minutes after the end of nebuli-
zation, these values were stable (42  12.4 vs 43.6  12.5
mm Hg). After 25 minutes, they returned to baseline in the
PGI2 group to 53.3  17.6 mm Hg and remained stable in
the placebo group at 43.5  13 mm Hg (Figure 1). There
was a significant positive correlation between the severity of
PH before the administration of inhaled PGI2 and the mag-
nitude of the decrease in sPAP (r  0.76, P  .01). Heart
rate decreased in the PGI2 group from 64.4  8.8 to 58.5 
11 beats/min (P  .002). It stayed stable thereafter until 25
minutes after inhaled PGI2, when it increased to 62.8 11.6
beats/min (P  .001). Mean PAP did not change signifi-
cantly after PGI2 administration nor did systemic arterial
pressures. Cardiac indexes remained unchanged throughout
the study. Compared with placebo, indexed RV stroke work
decreased after PGI2 inhalation from 10.7  4.57 to 7.8 
3.94 g  m  m2 (P  .003) and remained stable thereafter
for 25 minutes.
Oxygenation
Oxygenation data are given in Table 3. The Pao2 value at
baseline was significantly different on arrival in the operat-
ing room with a nasal cannula at 4 L/min of oxygen
(173.1  65.2 mm Hg in the PGI2 group vs 251.5  95.4
mm Hg in the placebo group, P  .05), but this difference
disappeared after induction of anesthesia with a fraction of
inspired oxygen of 100% (428.2  65.2 vs 443.7  64.9,
respectively; P  .6). Otherwise, oxygenation variables did
not change throughout the study.
TABLE 1. Demographic data of the study population
n Epoprostenol n Placebo P value
Age, y 10 65 11 10 58 12 .22
Sex
Male 5 50% 4 40% 1
Female 5 50% 6 60%
Weight, kg 10 76 17 10 70 20 .56
Height, m 10 1.65 0.11 10 1.63 0.08 .65
Parsonnet score 10 29.2 6.5 10 32.4 10.2 .4
Reoperation 3 30% 5 50% .65
Aspirin use 0 0% 3 30% .21
Preoperative heparin 3 30% 3 30% 1
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Echocardiography
Echocardiography data are given in Table 4. Of 240 images
taken, 43 were rejected according to the predefined criteria.
There was a 3% interobserver discordance. TEE examina-
tions were similar in both groups before and after inhalation
of PGI2 or placebo, but in the PGI2 group a tendency toward
improved fractional area change or systolic function was
noted for both the left and right ventricles. Also, in the PGI2
group the systolic portion of hepatic flow tended to increase,
and the diastolic portion remained stable compared with that
seen with placebo, which suggests improvement in RV
diastolic function, but this did not reach statistical signifi-
cance.
Platelet Aggregation
Platelet aggregation data are shown in Table 5. Platelet
aggregation studies showed a significant difference in plate-
let luminescence produced by collagen (0.8  0.2 nm in the
PGI2 group vs 1.2  0.5 nm in the placebo group, P 
.046), but this difference remained stable throughout the
study (0.7  0.3 vs 1.1  0.5 nm, respectively; P  .055).
Otherwise, platelet aggregation studies showed no dif-
ference between the 2 groups with either adenosine diphos-
phate, collagen, or arachidonic acid used as aggregants.
Surgical blood loss was similar in both groups for both the
intraoperative and postoperative periods.
Discussion
This is the first randomized controlled trial to examine
hemodynamic, echocardiographic, oxygenation, and plate-
let function effects of inhaled PGI2 versus placebo in pa-
tients after anesthesia induction and before cardiac surgery.
It confirms that inhaled PGI2 can be a selective pulmonary
vasodilator and decrease indexed RV stroke work. Our TEE
TABLE 2. Hemodynamic variations of the population throughout the study
T1 T2 T3 T4 T5
Epoprostenol
HR (beats/min) 66.1 9.7 64.4 8.8 58.5 11* 56.7 10.6 62.8 11.6†
SAP (mm Hg) 134.4 28.6 105.3 15 101.2 19.3 108.6 22 124.9 28
MAP (mm Hg) 85.9 14.6 67.9 11.5 63.8 10.5 69.7 13.7 82.6 19
CVP (mm Hg) 11.1 6.8 11 4.9 10.8 4.8 11.5 4.9 13.3 4.3
PAOP (mm Hg) 22.8 8.1 21.8 6.6 19 6.4 20.6 6.6 24.6 9
sPAP (mm Hg) 61.2 19 48.4 18§ 38.9 11.9¶ 42 12.4 53.3 17.6
MPAP (mm Hg) 41.5 9 32.9 9.2§ 28.2 8.2 30.4 8.4 36 11.1
CI (L  min1  m2) 2.5 0.7 2.2 0.6 2 0.5 2 0.6 1.9 0.5
EV (mL  beat1  m2) 69.4 20 65.4 17.3 62.9 17.6 66 19.2 56.7 17.7
SVRI (dyne  s  cm5) 2474 424.2 2078 566.6 2260 381.3 2460 719.7 3157 1249
PVRI (dyne  s  cm5) 683.5 449.1 451.7 315.6 404.9 250 398.2 266.6 555.4 347.3
LVSWI (g  m  m2) 33.1 16.1 21.7 8.6 22.5 10.8 24.3 11.6 24.6 12.3
RVSWI (g  m  m2) 15.5 6.3 10.7 4.6§ 7.8 3.9# 8.3 4.2 8.6 3.1
Placebo
HR (beats/min) 67.8 12.5 68.5 14.4 65.5 16 61.4 14.8 61.5 11.7
SAP (mm Hg) 142.2 26.4 118.4 24.1 119.6 23.1 117.4 24.6 119.1 22.1
MAP (mm Hg) 92 14.2 77.3 13.6 78.4 14.3 76.7 16.1 78.6 11
CVP (mm Hg) 14.4 7.1 11.3 5.2‡ 11.7 4.7 12.6 4.1 12.9 4.6
PAOP (mm Hg) 21.7 11.3 19.7 8 19.9 8.4 21.1 6.5 21.1 5.8
sPAP (mm Hg) 54.3 14.6 42.7 12.8‡ 41.3 15.2 43.6 12.5 43.5 13
MPAP (mm Hg) 38.4 9.9 30 9.6‡ 29.6 13.4 30.4 9.1 29.6 7.6
CI ((L  min1  m2) 2.8 0.8 2.7 0.8 2.5 0.7 2.4 0.7 2.2 0.6
EV (mL  beat1  m2) 73.2 15.7 67.7 18.9 68.5 20.2 68.1 18.5 63.6 15.4
SVRI (dyne  s  cm5) 2282 635.2 2128 708.3 2290 776.4 2497 786.8 2492 924.3
PVRI (dyne  s  cm5) 521.7 310 311.8 147.1 299.5 161.8 352.9 208.6 324.5 276.7
LVSWI (g  m  m2) 40.4 18.4 30.3 11.7 31 9.6 32 11.9 27.2 6.6
RVSWI (g  m  m2) 13.4 6.2 9.5 4.9‡ 8.8 5 9.5 5 7.8 3.9
HR, Heart rate; SAP, systemic arterial pressure; MAP, mean arterial pressure; CVP, central venous pressure; PAOP, pulmonary artery occlusion pressure;
MPAP, mean pulmonary arterial pressure; CI, cardiac index; EV, ejection volume; SVRI, systemic vascular resistance index; PVRI, pulmonary vascular
resistance index; LVSWI, LV stroke work index; RVSWI, RV stroke work index.
*P  .002 T2 to T3 in prostacyclin group.
†P  .001 T4 to T5 in prostacyclin group.
‡P  .001 T1 to T2 in placebo group.
§P  .001 T1 to T2 in prostacyclin group.
P  .001 T3 to T5 in prostacyclin group.
¶P  .002 T2 to T3 in prostacyclin group.
#P  .003 T2 to T3 in prostacyclin group.
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findings also suggest a tendency toward improvement of
both RV and LV systolic functions, as well as RV diastolic
function. The dose administered was safe, with no systemic
hypotension or any effect on platelet aggregation.
Inhaled PGI2 decreases PAP. This has been confirmed in
many animal18-20 and human12,21-24 studies. Because of this,
it reduces RV afterload and can improve RV systolic and
diastolic functions. In dogs having PH after hypoxic pul-
monary vasoconstriction, Zwissler and colleagues21 demon-
strated improvement of RV contraction indices through
reduction in RV afterload with a small dose of inhaled PGI2.
In human subjects one study showed improvement of RV
ejection fraction in patients having PH caused by pulmonary
fibrosis.23 Haraldsson and colleagues25 showed improve-
ment of RV performance with inhaled PGI2 in patients
having PH after cardiac surgery. Our study demonstrates a
reduction in indexed RV stroke work in patients before
cardiac surgery. The reduction in RV stroke work index was
Figure 1. sPAP variations of each patient before (T1) and 10 minutes after (T2) induction of anesthesia, after
nebulization of PGI2 or placebo (T3), and 15 (T4) and 25 (T5) minutes after nebulization.
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associated with a tendency to improve RV fractional area
change and also RV diastolic function.
Although the decrease in PAP we observed was modest,
we observed that its magnitude correlated with the severity
of PH. This suggests that the benefit of inhaled PGI2 might
be greater with patients with more advanced disease.
There was a statistically significant decrease in heart rate
after inhaled PGI2 administration as opposed to that seen
after placebo administration, but this was of no clinical
significance.
Theoretically, inhaled PGI2 should improve systemic
oxygenation by dilating pulmonary vessels in ventilated
areas. This has been demonstrated in many models of hyp-
oxia, including adult respiratory distress syndrome.6 It has
been noted, however, that in patients who are not hypox-
emic, as in our population, this effect is not always ob-
served.4,25
PGI2 is a powerful inhibitor of platelet aggregation. In
vitro, small concentrations of PGI2 can inhibit platelet ag-
gregation.11 However, when administered by means of in-
halation, this effect has not been shown to occur consistent-
ly.6,26,27 All previous platelet aggregation studies were done
on platelet-rich plasma. We chose to evaluate platelet ag-
gregation on whole blood because the platelet is then sur-
rounded by other blood constituents that might play a role in
modulating platelet aggregation. This might be more reflec-
tive of the in vivo condition.28 We did not show a significant
effect on platelet aggregation in our study. This suggests
that not enough drug actually reached systemic circulation
to have an effect on platelets. This, together with the similar
surgical blood losses observed in both groups, suggests that
the dose of inhaled PGI2 in the present study is safe.
Two patients died after the operation. One patient in the
PGI2 group had mitral valve replacement and a history of
prior aortic valve replacement, paroxysmal atrial fibrilla-
tion, and sleep apnea. The second patient, from the placebo
group, underwent aorta-coronary bypass surgery and had a
history of mitral commissurotomy, mitral valve replace-
ment, and chronic obstructive lung disease. They both died
of multiple-system organ failure. A 10% mortality rate was
expected in our population.1
Study Limitations
The main limitation of this study is the small sample size
that was calculated to observe a 20% decrease in sPAP. This
might not have been sufficient to observe a significant effect
on echocardiographic measurements or platelet function.
Only one dose was studied. We did not explore the
dose-response curve of inhaled PGI2. The dose used was
based on previous experience with the drug in both the
operating room and the intensive care unit. When adminis-
tering drugs by means of nebulization, it is very difficult to
determine the effective dose for many reasons. The quantity
of drug that actually reaches the lungs is highly variable. It
depends on the characteristics of the drug itself, the nebu-
lizer used, the flow of carrier gas to the nebulizer, the
TABLE 3. Arterial and venous blood gas evolution
T1 T2 T3 T4
Epoprostenol
PaO2 173.1 65.2* 428.2 65.2† 432.2 82 431.6 68.4
Arterial pH 7.41 0.03 7.44 0.02 7.46 0.02 7.45 0.03
PaCO2 46 4.2 42 2.3 39.4 3.7 41.7 6
Bicarbonate 29.8 2.8 28.3 1.6 28.1 2.1 28.9 2.5
BE 5.2 2.4 4.3 1.6 4.7 1.7 5.1 1.8
PvO2 41.9 6.1 50 7 46 4.6 45.6 5.7
Venous pH 7.39 0.03 7.39 0.02 7.42 0.02 7.41 0.02
PvCO2 53.1 3.8 50.5 3 46.9 4 49 5.4
PaCO2  PvCO2 6.4 4.2 8.5 3.5 7.5 2.2 7.3 1.9
Placebo
PaO2 251.5 95.4* 443.7 64.94† 425.9 88.75 438.3 80.62
Arterial pH 7.41 0.02 7.42 0.02 7.45 0.03 7.42 0.05
PaCO2 44.9 3.3 43.1 2.8 40.4 4.6 43 6.4
Bicarbonate 28.7 1.8 27.8 1.9 27.8 2 28.1 1.6
BE 4.2 1.6 3.6 1.7 4.1 1.7 3.9 1.3
PvO2 44.8 3.8 55.9 8 51.9 6.6 54.1 9.5
Venous pH 7.39 0.03 7.39 0.02 7.40 0.03 7.40 0.04
PvCO2 49.6 4.8 48.6 3.2 47 3.9 49.1 6.4
PaCO2  PvCO2 4.7 2.8 5.5 2.3 6.6 2.4 6.1 2.2
BE, Base excess; PvO2, venous oxygen partial pressure; PvCO2, venous carbon dioxide partial pressure; PaCO2  PvCO2, arteriovenous difference in carbon
dioxide partial pressure.
*P  .05 between both groups.
†P  .001 T1 to T2 in both groups.
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density of the carrier gas, the amount of drug remaining in
the nebulizer, and the humidity and temperature in the
nebulizer circuit.29,30 Particles of 1 to 5 m are considered
to be in the respirable range.29 We used high nebulizer flows
because this increases the proportion of particles produced
in the respirable range, and during mechanical ventilation, it
is known that less than 10% of the medication actually
reaches the alveolar epithelium. The 60-g dose we nebu-
lized over 10 minutes is approximately equal to 85 ng 
kg1  min1.
PGI2 might be an alternative to iNO. Both can induce
selective pulmonary vasodilatation. The effect of iNO re-
mains localized through inactivation by hemoglobin as soon
as it reaches the circulation. However, disadvantages related
to the use of iNO have been identified, such as the produc-
tion of toxic metabolites and methemoglobinemia when
given at high concentrations for a long period of time. It
requires costly and specialized equipment. Epoprostenol, on
the other hand, has no known toxic metabolites and very
few side effects. It can be administered by means of simple
nebulization with minimal equipment, which is an advan-
tage for use in the operating room. A full 24 hours of
treatment is estimated to cost approximately $115.00 CAN
(approximately $70.00 US).
Conclusion
Inhaled PGI2 reduces PAP in the preoperative period. By
doing so, improvements in RV function through a decrease
in indexed RV stroke work can be achieved. It is a safe
medication that does not increase platelet dysfunction or
perioperative bleeding. This exploratory trial confirms that
inhaled PGI2 can be safely studied in the postbypass period,
where treatment for unexpected PH can be encountered.
TABLE 4. TEE examination results
Left ventricle Right ventricle
n T2 n T3 n T2 n T3
Epoprostenol
FAC (%) 8 0.56 0.16 8 0.63 0.16 FAC (%) 7 0.47 0.07 7 0.54 0.08
LV ESA (cm2) 8 10.7 6.5 8 8.5 5.9 RV ESA (cm2) 7 7.2 1.5 7 6.2 2.4
LV EDA (cm2) 8 23.5 9.7 8 20.8 9.2 RV EDA (cm2) 7 13.4 1.8 7 13.2 3.4
MEW (cm/s) 6 138.8 66.8 6 133.7 46.4 HSW (cm/s) 9 11.9 26.7 10 14 17.8
MEW VTI (cm) 5 34.9 30.5 5 39.3 40.7 HSW VTI (cm) 9 3.4 6.9 9 2.7 3
MAW (cm/s) 6 78.9 39.7 6 72.9 38.9 HDW (cm/s) 9 20.7 11.8 10 19.7 8.7
MAW VTI (cm) 5 10 5.6 5 8.8 3.3 HDW VTI (cm) 9 5.9 2.8 9 5.4 2.2
PSW (cm/s) 9 18.6 55.9 8 25.7 62.3 HAW (cm/s) 5 17.5 3.2 5 17.7 6.7
PSW VTI (cm) 8 7.4 12.7 8 8.4 13.2 HAW VTI (cm) 5 2.1 0.9 4 2.5 1.6
PDW (cm/s) 9 51.1 26.2 9 50.9 28.1 TEW (cm/s) 5 55.7 24.5 3 52.3 17.5
PDW VTI (cm) 9 12.8 4.9 9 14.6 6.8 TEW VTI (cm) 4 11.3 3.7 3 11.3 3.8
PAW (cm/s) 6 33.8 18.9 6 37.1 19.2* TAW (cm/s) 3 40.8 2.9‡ 2 43.8 3.8‡
PAW VTI (cm) 6 3.4 1.5 6 4.5 2.4† TAW VTI (cm) 2 5.3 1.6 2 5.9 0.3
Placebo
FAC (%) 10 0.54 0.13 10 0.55 0.05 FAC (%) 8 0.45 0.08 7 0.48 0.12
LV ESA (cm2) 10 8.48 5.81 10 8.30 4.18 RV ESA (cm2) 8 7.56 3.52 7 6.83 3.77
LV EDA (cm2) 10 17.51 9.05 10 18.35 9.07 RV EDA (cm2) 8 13.9 6.83 7 12.44 4.52
MEW (cm/s) 8 135.5 34.56 8 130.9 37.04 HSW (cm/s) 10 16.28 12.08 10 13.7 8.72
MEW VTI (cm) 8 29.31 14.15 8 27.51 21.07 HSW VTI (cm) 9 3.96 3.8 10 3.46 2.84
MAW (cm/s) 6 92.6 42.66 6 84.43 35.49 HDW (cm/s) 10 17.33 5.99 9 31.51 47.42
MAW VTI (cm) 6 10.67 6.68 6 10.08 2.32 HDW VTI (cm) 9 4.89 2.2 9 4.39 2.14
PSW (cm/s) 10 39.28 16.08 10 43.22 24.59 HAW (cm/s) 8 17.08 9.82 6 12.57 4.15
PSW VTI (cm) 10 9.84 6.13 10 10.41 7.4 HAW VTI (cm) 7 2.21 0.7 6 1.99 0.65
PDW (cm/s) 10 50.06 12.71 10 49.84 12.07 TEW (cm/s) 8 47.56 17.26 6 48.68 10.77
PDW VTI (cm) 10 12.99 3.51 10 12.88 3.32 TEW VTI (cm) 7 9.46 5.2 6 10.4 2.4
PAW (cm/s) 8 22.76 7.52 7 19.71 8.8* TAW (cm/s) 7 35.44 11.02 4 32.05 6.8
PAW VTI (cm) 8 2.31 1.07 7 1.87 0.9† TAW VTI (cm) 6 5.3 1.69 4 4.49 1.07
FAC, Fractional area change; ESA, end-systolic area; EDA, end-diastolic area; MEW, mitral E wave; MAW, mitral A wave; PSW, pulmonary S wave; PDW,
pulmonary D wave; PAW, pulmonary A wave flow; HSW, hepatic S wave; HDW, hepatic D wave; HAW, hepatic A wave; TEW, tricuspid E wave; TAW,
tricuspid A wave; VTI, velocity time interval; LV, left ventricular; RV, right ventricular.
*P  .05 at T3 between both groups.
†P  .02 at T3 between both groups.
‡P  .01 T2 to T3 in epoprostenol group.
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TABLE 5. Whole blood platelet aggregation impedance and
luminescence results
T2 T3
Epoprostenol
ADP imp () 16.67 6.74 14.9 6.38
ADP lum (nm) 0.69 0.23 0.63 0.2
Collagen imp () 36.44 6.8 36.1 5.68
Collagen lum (nm) 0.75 0.26* 0.71 0.26†
AA imp () 9.78 8.69 6.8 7.79
AA lum (nm) 0.81 0.47‡ 0.72 0.41
Platelet count 126.3 32.64 126.8 36.32§
Blood loss
Intraoperative 685.5 350.9
Postoperative 725.5 676.3
Placebo
ADP imp () 19.7 6.4 17.3 7.72
ADP lum (nm) 0.82 0.33 0.85 0.33
Collagen imp () 33 3.89 35.9 6.08
Collagen lum (nm) 1.17 0.55*‡ 1.1 0.52†‡
AA imp () 13.4 9.99 13.3 9.4
AA lum (nm) 1.38 0.76*§ 1.1 0.6§
Platelet count 160.9 40.19 164 40.25†
Blood loss
Intraoperative 660 504.3
Postoperative 664 352
ADP, Adenosine diphosphate; imp, impedance; lum, luminescence; AA,
arachidonic acid.
*P  .05 between both groups at T2.
†P  .055 between both groups at T3.
‡P  .05 T2 to T3 in placebo group.
§P  0.01 T2 to T3 in placebo group.
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